Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Change in Receivables (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Change in Receivables for 16 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 63.16% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.7 million through Dec 2025, up 236.54% year-over-year, with the annual reading at $21.7 million for FY2025, 236.54% up from the prior year.
  • Change in Receivables hit $2.1 million in Q4 2025 for Ligand Pharmaceuticals, down from $16.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $20.4 million in Q2 2022 to a low of -$43.6 million in Q1 2022.
  • Historically, Change in Receivables has averaged $204700.0 across 5 years, with a median of $2.4 million in 2022.
  • Biggest five-year swings in Change in Receivables: tumbled 1709.95% in 2022 and later surged 757.15% in 2024.
  • Year by year, Change in Receivables stood at $19.8 million in 2021, then plummeted by 275.8% to -$34.8 million in 2022, then soared by 91.85% to -$2.8 million in 2023, then soared by 299.82% to $5.7 million in 2024, then plummeted by 63.16% to $2.1 million in 2025.
  • Business Quant data shows Change in Receivables for LGNDZ at $2.1 million in Q4 2025, $16.3 million in Q3 2025, and $2.8 million in Q2 2025.